As previously reported, Guggenheim upgraded Arvinas to Buy from Neutral with a $40 price target. The firm is positive on the probability of success for ARV-471 ahead of topline results for a Phase 3 trial for breast cancer less than a year away and adds that data from the Veritac-2 Phase 3 trial adds a “significant near-term catalyst.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARVN: